Filing Details

Accession Number:
Form Type:
Zero Holdings:
Publication Time:
2021-02-18 20:40:10
Reporting Period:
Accepted Time:
2021-02-18 20:40:10
Original Submission Date:
SEC Url:
Form 4 Filing
Cik Name Symbol Sector (SIC) IRS No
1645460 Cue Biopharma Inc. CUE () 4/A
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1571862 Kenneth Pienta C/o Cue Biopharma, Inc.
21 Erie Street
Cambridge MA 02139
Chief Medical Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2021-01-20 2,720 $2.86 4,720 No 4 M Direct
Common Stock Disposition 2021-01-20 2,720 $15.07 2,000 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (right to buy) Disposition 2021-01-20 2,720 $0.00 2,720 $2.86
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
17,280 2023-11-16 No 4 M Direct
  1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 20, 2020.
  2. This option exercise was omitted from the reporting person's original Form 4.
  3. This transaction was incorrectly reported using Code "P" in the reporting person's original Form 4.
  4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.02 to $15.26, inclusive. The reporting person undertakes to provide to Cue Biopharma, Inc., any security holder of Cue Biopharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (4) to this Form 4.
  5. The option, representing a right to purchase a total of 20,000 shares, became exercisable in full on November 16, 2017.